Group 1 - JD Health's stock rose over 5% following the release of its Q3 2025 earnings, with a current price of HKD 67.9 and a trading volume of HKD 253 million [1] - For Q3 2025, JD Health reported revenue of RMB 17.12 billion, a year-on-year increase of 28.7%, and operating profit of RMB 1.243 billion, up 125.3% year-on-year [1] - The company signed strategic cooperation agreements with major pharmaceutical companies such as Eli Lilly, Innovent Biologics, Eisai China, and Bayer China, further establishing its position as the "first station for the online launch of new specialty drugs" [1] Group 2 - In September 2025, JD Health partnered with Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital to create a leading smart outpatient service platform [2] - The collaboration aims to implement JD's AI product "JD Zhuoyi" in outpatient services, establishing a comprehensive AI accompaniment system for patients [2] - Both parties will deepen cooperation in telemedicine and explore new models of "Internet + healthcare" services [2]

Group 1 - JD Health reported a revenue of 17.12 billion yuan for Q3 2025, representing a year-on-year growth of 28.7%, with operating profit increasing by 125.3% to 1.24 billion yuan [1] - The company signed strategic cooperation agreements with major pharmaceutical companies including Eli Lilly, Innovent Biologics, and Bayer China, reinforcing its position as the first choice for the online launch of new specialty drugs [1] - JD Health also launched several health products online, including new generation vitamins and specialized medical foods, further establishing its market presence [1] Group 2 - In September 2025, JD Health formed a Smart Interconnection Ecological Alliance with leading medical device brands to create a comprehensive smart blood glucose management system, aiming to expand into other health monitoring areas [2] - A partnership was established with Huazhong University of Science and Technology to develop a leading smart outpatient service platform, enhancing patient experience through AI-driven services [2] Group 3 - Zhiyun Health announced a service cooperation agreement with JD Health to enhance online sales channels for its products, leveraging JD Health's extensive user base and platform resources [3] - The opening of online medical insurance purchasing rights is seen as a significant short-term catalyst for the industry, with JD Health positioned to benefit from this trend [3][4] - JD Health is recognized as a leading player in the pharmaceutical e-commerce sector, expected to gain from the increasing online penetration of pharmaceutical products and the opening of online medical insurance payment permissions [4]

Group 1 - JD Health reported Q3 2025 revenue of 17.12 billion RMB, a year-on-year increase of 28.7%, and operating profit of 1.243 billion RMB, up 125.3% year-on-year [1] - The company signed strategic cooperation agreements with major pharmaceutical companies such as Eli Lilly, Innovent Biologics, Eisai China, and Bayer China, further establishing its position as the first choice for the online launch of new specialty drugs [1] - JD Health launched various health products, including new generation vitamins and specialized medical foods, achieving their online debut on the platform [1] Group 2 - In September 2025, JD Health partnered with Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital to create a leading smart outpatient service platform [2] - The collaboration aims to implement the "JD Zhuoyi" AI product in outpatient services, establishing a comprehensive AI accompaniment system for patients [2] - Both parties will deepen cooperation in telemedicine, exploring new models of "Internet + healthcare" services [2]

JD Health International Inc. 京東健康股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6618（港幣櫃台）及86618（人民幣櫃台）） 內幕消息 2025 年第三季度之未經審計最新資料 本公告乃由京东健康股份有限公司（「本公司」或「京東健康」，連同其子公司及關聯併表 實體統稱「本集團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規 則」）第13.09條及香港法例第571章證券及期貨條例第XIVA部項下的內幕消息條文（定義 見上市規則）而刊發。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 業務最新資料 2025年第三季度，京東健康與禮來、信達生物、衛材中國及拜耳中國等知名藥企簽署戰 略合作協定。衛材藥企旗下原研新藥達衛可® （萊博雷生片）、恒瑞旗下乾眼症新藥恆沁® （全氟己基辛烷滴眼液）、拜耳旗下達喜® 乳果糖等新藥也選擇在京東健康全網首發，繼 續鞏固京東健康「新特藥全網首發第一站」心智。除藥 ...